ESR1 and triple-negative breast carcinoma: Therapeutic strategies that target the estrogen receptor (ER) and HER2 signaling have improved survival for patients with ER-positive and HER2 over-expressing BC2, but tumors that do not express these proteins (so-called triple negative breast cancer, TNBC) often have a poor outcome.